In the latest episode of The Line Podcast, Matt Gurney and Jen Gerson begin with some news close to home: The Line gets hacked! Well, almost. Luckily, our defences held. Unfortunately, the list of people who might want to hack us is longer than we'd like. We piss a lot of people off.

This episode is brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs carry real risk of delays and cost overruns, and we cannot afford to spend years designing a reactor before construction begins. That is why Cameco believes the AP1000 reactor is the right choice for Canada. It is already operating globally and ready now, with 100 percent Canadian ownership and strong participation from Canadian suppliers.

The AP1000 reactor means job creation and supplier contracts, energy security at home, and significant investment staying right here in Canada.

A proven design, built on time and on budget. That is how we build Canada.

Learn more at ap1000.cameco.com.

Then it's on to the main event: Mark Carney goes to New York and talks to American reporters, including about the possibility of a U.S. attack on Canada. Matt is irritated by the reaction back home. The military considering bizarre and unlikely scenarios isn't evidence that the prime minister has lost his mind. It's literally the military's job to think about weird scenarios before they happen. In attacking Carney over this, Matt argues, his critics are really attacking the Canadian military for doing exactly what Canadians pay it to do.

Next, Jen provides an update from Alberta, where there is, as usual, a lot going on. She suspects Danielle Smith may be coming a little unhinged. Matt, ever the diplomat, decides to court controversy by asking when so many Albertans turned into Torontonians, terrified of saying anything that might offend somebody. You guys used to be braver than that.

Finally, your hosts discuss the horrific attack on a synagogue in Belleville, Ontario, before turning to two media stories they think listeners should know about. And Matt has a question for Jen: is the CBC actively trying to get itself scrapped?

This episode is also brought to you by BioCanRx. We’ve been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September we’re focusing on the “made-in-Canada” part. One way to leverage existing Canadian government investments in biomanufacturing would be to make it easier for Canadian innovators to develop their discoveries into therapies here in Canada.

Aside from organizations like BioCanRx, there are few funding sources for the “translational research” activities necessary to build the significant body of evidence required for clinical trial approval from Health Canada — without which these therapies could never reach patients. If funding mechanisms are created to support translational research in Canada, more Canadian discoveries can generate work for Canada’s biomanufacturing facilities — leading to more sovereign capacity, and more therapies made in Canada for Canadian patients.

But how could we make sure new investments aren’t wasted? More on that next week. Visit BioCanRx.com to learn more.

All that and more in the latest episode of The Line Podcast. Check out, but do not hack!, our main page at ReadTheLine.ca. Like and subscribe!

In this episode of On The Line, Jen Gerson checks in with Greenland and Europe. Canadians seem increasingly open to closer ties with non-U.S. Western allies — but what do those allies think about us?

First, Markus Bernsen joins Jen to discuss the reported U.S.-Greenland agreement, what remains unknown, and why the negotiations have caused so much anxiety in Greenland and Denmark. They discuss military access, investment, sovereignty, and the damage already done to the Denmark-U.S. relationship.

This episode is also brought to you by the Forest Products Association of Canada. Every budget season brings endless ideas for how Ottawa should spend. But some of the best ways to strengthen Canada’s economy don’t require a massive price tag.

For Canada’s forest products sector, real growth starts with dismantling made-in-Canada barriers: cutting regulatory duplication, fixing supply chain bottlenecks, securing predictable, cost-competitive access to fibre, and creating more certainty for investment.

We can’t control every global challenge facing our industry, but we can remove the barriers created right here at home.

Discover how smarter policy drives economic growth at FPAC.ca.

Then Brussels-based foreign correspondent Jack Parrock joins Jen to discuss Canada’s push for closer ties with the European Union. What would “associate membership” actually mean? How much is substance and how much is symbolism? And could Canada and Europe build deeper links in trade, payments and defence as both reconsider their dependence on the United States?

From Greenlandic sovereignty to diplomacy in Strasbourg, it’s a look at how the Western alliance is being reshaped — and where Canada might fit.

Check out our main page at ReadTheLine.ca, and as always, like and subscribe. Stay tuned Friday for the next episode of The Line Podcast.

In the latest episode of The Line Mega Productivity Podcast, recorded on September 18th, 2026, prospective associate EU members Matt Gurney and Jen Gerson begin with Prime Minister Mark Carney’s trip to the continent. The reception was remarkably warm, as Canada and Europe explore a much closer strategic relationship.

This episode is brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs carry real risk of delays and cost overruns, and we cannot afford to spend years designing a reactor before construction begins. That is why Cameco believes the AP1000 reactor is the right choice for Canada. It is already operating globally and ready now, with 100 percent Canadian ownership and strong participation from Canadian suppliers.

The AP1000 reactor means job creation and supplier contracts, energy security at home, and significant investment staying right here in Canada.

A proven design, built on time and on budget. That is how we build Canada.

Learn more at ap1000.cameco.com.

Your hosts discuss the trip, the PMO’s continuing inability to develop a workable communications strategy and the credibility problems that creates. But the most fascinating part may be the American reaction. Donald Trump has now threatened retaliation over Canada’s growing ties with Europe. Matt and Jen wonder: is Washington finally beginning to realize just how badly it may have miscalculated?

Next, they turn to the Canada Investment Summit hosted by the prime minister in Toronto. There’s a lot to like about the ambition behind it, your hosts agree — but Canada now has to actually deliver the projects it is promising. And then there’s Stephen Harper. The former Conservative prime minister closed the summit by praising the initiative and arguing that Canada must reduce its reliance on the United States. Jen connects Harper’s remarks to a point Matt made in his column this week and goes considerably further: did Harper just politely drive a stake through the heart of Pierre Poilievre’s political career? Jen thinks so, and says so on the record: it’s over, Tories. Poilievre is never going to win. Move on.

Finally, Matt provides a quick update on some increasingly serious warnings from Canada’s European allies about the possibility of Russian attacks against NATO territory. Jen then brings things home with a major update from Alberta, now just one month away from its October 19 referendum.

This episode is brought to you by BioCanRx. We’ve been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September we’re focusing on the “made-in-Canada” part.

Federal and provincial governments have made strong investments in the biomanufacturing sector, but Canada’s drug development ecosystem has contracted over time, and there is not yet enough domestic demand to fully utilize many of these advanced biomanufacturing facilities. This becomes a sovereignty problem. If our biomanufacturing facilities can’t remain in operation, we lose the ability to develop and manufacture homegrown therapies. We wait for therapies developed in other countries to make their way here –– with no control over when that might happen. BioCanRx requires the research projects it funds to work with Canadian facilities whenever possible, which has helped build and sustain networks across Canada –– but there is still a lot of untapped potential.

How can we make sure our infrastructure isn’t sitting idle? More on that next week. Visit BioCanRx.com to learn more.

All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. Like and subscribe!

#TheLinePodcast #MarkCarney #PierrePoilievre #StephenHarper #CanadianPolitics #CanadaUSRelations #Europe #Russia #AlbertaPolitics #CurrentAffairs